0000886163-26-000034
SEC filingLigand delivered a materially improved Q1 2026, with revenue up 14.1% and operating income swinging from a $36.2M loss to a $17.4M profit — driven by royalty growth and the absence of a large prior-year R&D funding charge.
Net income improved to a $13.3 million loss in Q1 2026, compared to a $42.5 million loss in Q1 2025 — a 68.6% improvement in magnitude. Diluted EPS improved to $(0.67), versus $(2.21) in the prior year. These improvements reflect the same underlying drivers as operating income: the non-recurrence of the prior-year R&D funding charge and stronger royalty performance. However, net income remains negative due to ongoing investments in origination and portfolio management functions, including higher employee-related costs and share-based compensation.
Net cash provided by operating activities was $48.7 million in Q1 2026, a substantial improvement from a use of $25.4 million in Q1 2025. This reflects both higher royalty receipts and favorable changes in working capital and non-cash adjustments. Capital expenditures were minimal at $228,000, resulting in free cash flow of $48.5 million. This level of cash generation underscores the capital-light nature of Ligand’s royalty-centric model and provides significant flexibility for strategic deployment without reliance on external financing.
As of March 31, 2026, Ligand maintained a strong liquidity position, supported by its cash generation profile and conservative financial policies. The Company maintains investment guidelines focused on safety of principal and liquidity, governing the diversification and maturities of its short-term investment portfolio.